The role of HPV vaccination in the prevention of anal dysplasia

Preventing infection with HPV is likely the best strategy to decrease the incidence of anal cancer. The qvHPV and 9vHPV vaccines are highly immunogenic with the same serious adverse event rates as placebo. The qvHPV vaccine has been FDA approved since 2006 for the prevention of cervical, vaginal and vulvar cancer and anogenital warts in women from 9 –26 years of age related to HPV types 6, 11, 16 and 18. In 2009 it was FDA approved for prevention of anogenital warts in men and anogenital dysplasia in men and women 9–26 years of age related to the same HPV types.
Source: Seminars in Colon and Rectal Surgery - Category: Gastroenterology Authors: Source Type: research